Neuroscientific Biopharmaceuticals Ltd

AU:NSB Australia Biotechnology
Market Cap
$18.74 Million
AU$30.26 Million AUD
Market Cap Rank
#27176 Global
#660 in Australia
Share Price
AU$0.09
Change (1 day)
+3.41%
52-Week Range
AU$0.03 - AU$0.25
All Time High
AU$0.52
Categories
Companies in Australia Biotechnology
About

NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated … Read more

Neuroscientific Biopharmaceuticals Ltd (NSB) - Net Assets

Latest net assets as of June 2025: AU$16.81 Million AUD

Based on the latest financial reports, Neuroscientific Biopharmaceuticals Ltd (NSB) has net assets worth AU$16.81 Million AUD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$16.96 Million) and total liabilities (AU$149.22K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$16.81 Million
% of Total Assets 99.12%
Annual Growth Rate 72.49%
5-Year Change 15.13%
10-Year Change N/A
Growth Volatility 207.83

Neuroscientific Biopharmaceuticals Ltd - Net Assets Trend (2016–2025)

This chart illustrates how Neuroscientific Biopharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Neuroscientific Biopharmaceuticals Ltd (2016–2025)

The table below shows the annual net assets of Neuroscientific Biopharmaceuticals Ltd from 2016 to 2025.

Year Net Assets Change
2025-06-30 AU$16.81 Million +214.26%
2024-06-30 AU$5.35 Million +13.98%
2023-06-30 AU$4.69 Million -14.96%
2022-06-30 AU$5.52 Million -62.20%
2021-06-30 AU$14.60 Million +300.20%
2020-06-30 AU$3.65 Million -27.89%
2019-06-30 AU$5.06 Million +590.89%
2018-06-30 AU$732.52K +36.72%
2017-06-30 AU$535.79K +330.47%
2016-06-30 AU$124.47K --

Equity Component Analysis

This analysis shows how different components contribute to Neuroscientific Biopharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1985233800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$34.26 Million 203.74%
Other Comprehensive Income AU$5.84 Million 34.74%
Total Equity AU$16.81 Million 100.00%

Neuroscientific Biopharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Neuroscientific Biopharmaceuticals Ltd ranked by their market capitalization.

Company Market Cap
MGB Bhd
KLSE:7595
 		$13.62 Million
Hilan Ltd
TA:HLAN
 		$13.62 Million
Whetron Electronics Co.,Ltd.
TWO:6722
 		$13.62 Million
MegaMD Co. Ltd
KQ:133750
 		$13.62 Million
Omiris AG
F:HBD1
 		$13.61 Million
The Ruby Mills Limited
NSE:RUBYMILLS
 		$13.60 Million
Trimitra Prawara Goldland Tbk Pt
JK:ATAP
 		$13.60 Million
Precise Biometrics AB (publ)
PINK:PRBCF
 		$13.59 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Neuroscientific Biopharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 5,350,190 to 16,813,513, a change of 11,463,323 (214.3%).
  • Net loss of 1,845,513 reduced equity.
  • Share repurchases of 215,000 reduced equity.
  • New share issuances of 3,504,000 increased equity.
  • Other comprehensive income increased equity by 3,968,346.
  • Other factors increased equity by 6,051,490.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-1.85 Million -10.98%
Share Repurchases AU$215.00K -1.28%
Share Issuances AU$3.50 Million +20.84%
Other Comprehensive Income AU$3.97 Million +23.6%
Other Changes AU$6.05 Million +35.99%
Total Change AU$- 214.26%

Book Value vs Market Value Analysis

This analysis compares Neuroscientific Biopharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.79x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 53.80x to 0.79x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-06-30 AU$0.00 AU$0.09 x
2017-06-30 AU$0.01 AU$0.09 x
2018-06-30 AU$0.01 AU$0.09 x
2019-06-30 AU$0.07 AU$0.09 x
2020-06-30 AU$0.05 AU$0.09 x
2021-06-30 AU$0.10 AU$0.09 x
2022-06-30 AU$0.04 AU$0.09 x
2023-06-30 AU$0.03 AU$0.09 x
2024-06-30 AU$0.04 AU$0.09 x
2025-06-30 AU$0.11 AU$0.09 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Neuroscientific Biopharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -10.98%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1111.22%
  • • Asset Turnover: 0.01x
  • • Equity Multiplier: 1.01x
  • Recent ROE (-10.98%) is above the historical average (-60.85%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 -82.75% -88.79% 0.47x 1.98x AU$-115.45K
2017 -48.74% -686.70% 0.07x 1.08x AU$-314.70K
2018 -127.15% -3225.59% 0.04x 1.10x AU$-1.00 Million
2019 -32.78% -4901.18% 0.01x 1.01x AU$-2.17 Million
2020 -78.62% -3761.64% 0.02x 1.02x AU$-3.23 Million
2021 -21.76% -331.47% 0.06x 1.02x AU$-4.64 Million
2022 -189.05% -15244.70% 0.01x 1.40x AU$-10.99 Million
2023 -22.77% -21.58% 0.94x 1.13x AU$-1.54 Million
2024 6.06% 14.66% 0.41x 1.02x AU$-210.81K
2025 -10.98% -1111.22% 0.01x 1.01x AU$-3.53 Million

Industry Comparison

This section compares Neuroscientific Biopharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $31,815,679
  • Average return on equity (ROE) among peers: -60.84%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Neuroscientific Biopharmaceuticals Ltd (NSB) AU$16.81 Million -82.75% 0.01x $13.62 Million
Adalta Ltd (1AD) $2.03 Million -265.03% 1.74x $171.91K
Algorae Pharmaceuticals Ltd (1AI) $2.88 Million -33.65% 0.18x $9.99 Million
ACRUX Ltd (ACR) $17.49 Million -17.99% 0.05x $2.16 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $11.42 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $39.76 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $718.75K
Bio-Gene Technology Ltd (BGT) $4.25 Million -56.43% 0.18x $2.33 Million
BTC Health Ltd (BTC) $11.34 Million -4.81% 0.03x $364.22
Cambium Bio Ltd (CMB) $8.27 Million -79.86% 0.16x $8.11 Million
Clinuvel Pharmaceuticals Ltd (CUV) $240.81 Million 15.02% 0.13x $251.65 Million